유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

mérial - lammaste katarraalse palaviku-viiruse serotüüp-2 antigeeni, lammaste katarraalse palaviku-viiruse serotüüp-4 antigeeni - lammaste katarraalse palaviku viirus, inaktiveeritud viiruse vaktsiinide, immunoloogilised ravimid jaoks ovidae - lambad - lammaste aktiivne immuniseerimine viiraemia ennetamiseks ja lammaste katarraalse palaviku viiruse serotüüpide 2 ja 4 põhjustatud kliiniliste tunnuste vähendamiseks.

에스토니아 - 에스토니아어 - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 5mg 28tk; 5mg 30tk

에스토니아 - 에스토니아어 - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 10mg 30tk; 10mg 56tk

에스토니아 - 에스토니아어 - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 15mg 56tk; 15mg 28tk; 15mg 30tk

에스토니아 - 에스토니아어 - Ravimiamet

pharmaceutical works polpharma s.a. - olansapiin - suus dispergeeruv tablett - 20mg 30tk; 20mg 56tk; 20mg 28tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

sanofi winthrop industrie - aspartinsuliin - diabeet mellitus - diabeetis kasutatavad ravimid - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

에스토니아 - 에스토니아어 - Ravimiamet

sopharma ad - amikatsiin - süste-/infusioonilahus - 250mg 1ml 4ml 50tk; 250mg 1ml 2ml 100tk; 250mg 1ml 2ml 10tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogreelvesinikkloriid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombootilised ained - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmiin - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - kerge kuni mõõdukalt raskekujulise alzheimeri tõve sümptomaatiline ravi. sümptomaatiline ravi kerge kuni mõõdukalt raske dementsuse patsientidel, kellel on idiopaatiline parkinsoni tõbi.

에스토니아 - 에스토니아어 - Ravimiamet

pharmaswiss ceska republika s.r.o. - pemetrekseed - infusioonilahuse kontsentraadi pulber - 500mg 1tk